Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Bellerophon Therapeutics, Inc. (NASDAQ: BLPH).

Full DD Report for BLPH

You must become a subscriber to view this report.


Recent News from (NASDAQ: BLPH)

Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference
WARREN, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will present the previously reported top-line results from its Pha...
Source: GlobeNewswire
Date: May, 16 2018 08:30
Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results
WARREN, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter ende...
Source: GlobeNewswire
Date: May, 10 2018 08:45
FDA signs off on design of Phase 2b study of INOpulse in PH-COPD
Bellerophon Therapeutics ( BLPH -1.3% ) announces that the FDA has OK'd the key aspects of its planned Phase 2b clinical trial assessing INOpulse in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). More news on: Bellerophon Therapeut...
Source: SeekingAlpha
Date: May, 08 2018 10:38
Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
WARREN, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that, following the receipt of minutes from a recent meeting with the U.S....
Source: GlobeNewswire
Date: May, 08 2018 08:30
Bellerophon Therapeutics (BLPH) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
The following slide deck was published by Bellerophon Therapeutics in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 11 2018 14:16
Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference
WARREN, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a ...
Source: GlobeNewswire
Date: April, 03 2018 08:30
Blog Exposure - Intercept Pharma to Present Multiple New Ocaliva Data at International Liver Congress 2018
Stock Monitor: Bellerophon Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on Intercept Pharma, Inc. (NASDAQ: ICPT ). If you want access to this report all you need to do is sign up now by c...
Source: ACCESSWIRE IA
Date: March, 27 2018 07:00
Bellerophon Therapeutics reports Q4 results
Bellerophon Therapeutics (NASDAQ: BLPH ): Q4 EPS of -$0.44 Cash and cash equivalents $28.83M Press Release More news on: Bellerophon Therapeutics, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: March, 15 2018 16:49
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
WARREN, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter a...
Source: GlobeNewswire
Date: March, 15 2018 16:45
Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results
Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com...
Source: SeekingAlpha
Date: January, 31 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-182.452.392.502.36221,292
2018-05-172.392.432.442.30478,547
2018-05-162.252.312.482.24941,512,933
2018-05-152.232.2252.292.2081,241
2018-05-142.212.222.23992.1823,566

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-1841,91090,83146.1406Short
2018-05-1765,995209,52931.4968Cover
2018-05-16414,942768,16254.0175Short
2018-05-1520,78242,80248.5538Short
2018-05-144,6149,07350.8542Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BLPH.


About Bellerophon Therapeutics, Inc. (NASDAQ: BLPH)

Logo for Bellerophon Therapeutics, Inc. (NASDAQ: BLPH)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $126,785,855 - 05/11/2018
  • Issue and Outstanding: 57,369,165 - 03/10/2018

 


Recent Filings from (NASDAQ: BLPH)

Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: May, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 16 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 05 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 05 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018

 

 


Daily Technical Chart for (NASDAQ: BLPH)

Daily Technical Chart for (NASDAQ: BLPH)


Stay tuned for daily updates and more on (NASDAQ: BLPH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BLPH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BLPH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of BLPH and does not buy, sell, or trade any shares of BLPH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/